Stock Analysis
- Denmark
- /
- Life Sciences
- /
- CPSE:GUBRA
Gubra Full Year 2023 Earnings: kr.2.94 loss per share (vs kr.0.37 profit in FY 2022)
Gubra (CPH:GUBRA) Full Year 2023 Results
Key Financial Results
- Revenue: kr.205.0m (up 2.8% from FY 2022).
- Net loss: kr.44.5m (down from kr.4.31m profit in FY 2022).
- kr.2.94 loss per share (down from kr.0.37 profit in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Gubra shares are up 17% from a week ago.
Risk Analysis
Be aware that Gubra is showing 1 warning sign in our investment analysis that you should know about...
Valuation is complex, but we're helping make it simple.
Find out whether Gubra is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About CPSE:GUBRA
Gubra
Operates as a biotech company with two primary areas of business: pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs in Denmark and internationally.
Flawless balance sheet low.